What are the opening hours?

Monday 9am - 5pm Tuesday 9am - 5pm Wednesday 9am - 5pm Thursday 9am - 5pm Friday 9am - 5pm Saturday 10am - 5pm Sunday 9am - 5pm

TESS Research Foundation for Slc13a5 Epilepsy

Home
United States
Menlo Park, CA
TESS Research Foundation for Slc13a5 Epilepsy

Call Directions Website Contact the organization

TESS Research Foundation is a 501(c)(3) nonprofit organization determined to help families affected by SLC13A5 Epilepsy (a Citrate Transporter Disorder).

TESS Research Foundation, a 501(c)(3) tax exempt public charity, is determined to improve the lives of those affected by SLC13A5 Epilepsy (Citrate Transporter Disorder). We do this by funding research, spreading awareness, and supporting children with SLC13A5 Epilepsy and their families. Since 2015, we have gone from identifying the gene responsible for SLC13A5 Epilepsy to receiving FDA approval to start a gene therapy clinical trial in 2026. We have awarded more than $2 million in research grants and are connecting a global community of scientists. We do this across countries because SLC13A5 Epilepsy does not know geographic boundaries. We do this collaboratively because it takes a team to improve treatments and find a cure. We do this with urgency because our loved ones are sick now. We will have succeeded when all children with SLC13A5 Epilepsy can lead healthy and independent lives.

10/29/2026

🌟 Team TESS is at the Galien Patient Summit in NYC! 🌟
We're thrilled to join patient advocates, researchers, and healthcare innovators today to champion the power of patients in medical innovation!
🏆 We're also incredibly honored that our project, "Powered by Patients: TSHA-105 Gene Therapy for SLC13A5 Epilepsy," has been nominated for the inaugural Prix Galien Patient First Award, honoring Michael J. Fox and celebrating patient-centered innovation.
This recognition belongs to our TESS Superheroes, their families, researchers, donors, advocates, and everyone who has helped make this journey possible.

10/28/2026

🌟 It's a BIG week for TESS!🌟

This afternoon, our Scientific Director, Dr. Tanya Brown, had the honor of delivering in-person public comments at the FDA's Rare Disease Framework Initiative Public Meeting.🧬

Tanya highlighted the unique challenges and considerations facing rare disease patient advocacy organizations leading the way in gene therapy and drug development.

We are grateful to the FDA for its commitment to advancing rare disease treatments and for the opportunity to bring the patient advocacy perspective into these important conversations.

Together, we're working toward a future where even the rarest diseases have hope for treatment!💜

🔗 Read the FDA's white paper, A New Framework for Rare Disease Review: https://buff.ly/aiaUfxW

10/28/2026

🗣️BREAKING NEWS: THE FIRST PATIENT HAS RECEIVED GENE THERAPY FOR SLC13A5 EPILEPSY! 💜🎉

A dream more than a decade in the making is finally becoming a reality!

We are OVERJOYED to announce that the first patient has received the first-ever gene therapy for SLC13A5 Epilepsy at UT Southwestern and Children’s Health in Dallas! 🧬

This groundbreaking achievement brings incredible hope to our TESS Superheroes and families around the world.

YOU helped make it possible! Your generosity, advocacy, and unwavering belief in our mission have brought us to this extraordinary achievement.

🚀This is only the beginning! We are on track to dose a second patient before the end of the year, bringing us closer to making this potential treatment available to every TESS Superhero who needs it.

From the bottom of our hearts, THANK YOU for helping us make history! 💜
🔗 Learn more: https://buff.ly/d3x7aVw

10/27/2026

🚀BIG NEWS: TESS IS ON THE FAST TRACK TO HOPE! 🎉
We are thrilled to announce that TSHA-105, our investigational gene therapy for SLC13A5 Epilepsy, has received Fast Track designation from the FDA!
What does this mean?
Fast Track is designed to help promising treatments for serious conditions reach patients sooner by allowing more frequent communication with the FDA and opportunities for a faster review process.
This is another exciting step forward in our mission to have an approved treatment for our TESS Superheroes.
💜 From the first-ever clinical trial and now Fast Track designation — the momentum continues!
Thank you to our incredible families, researchers, partners, and supporters for helping make this progress possible!

https://buff.ly/B6PnvQe

10/26/2026

Happy birthday to TESS Supehero Jacob! 🎊 We hope this year is full of laughter, love, and lots of wonderful days! 💙

10/25/2026

Happy birthday to TESS Superhero Artash! 🎈 We hope this year brings many new happy firsts! 💜

10/25/2026

Happy birthday to TESS Superhero Amrik! 🎂 Wishing you a year full of all of your favorite things and people! 👏

10/24/2026

We love sharing the incredible stories of our TESS Superheroes and their journeys! Whether you’d like to feature your family’s story or have us celebrate your TESS Superhero’s birthday with a special post, we’d love to hear from you! 🙏

Interested? Fill out our Google Form: https://bit.ly/4w9zKoO 🌟

Thank you for being part of ! 💜

10/23/2026

👻🎃A Haunted House but SLC13A5 Epilepsy Edition….what would you add?? Let us know in our comments below💜👻🎃

10/22/2026

Happy birthday to Dr. Brenda Porter! 🎂 You make the world a better place and we are so lucky that you are such an instrumental part of TEAM TESS! 👏 We 💜 you!

Address

PO Box 53
Menlo Park, CA
94026

Opening Hours

Monday	9am - 5pm
Tuesday	9am - 5pm
Wednesday	9am - 5pm
Thursday	9am - 5pm
Friday	9am - 5pm
Saturday	10am - 5pm
Sunday	9am - 5pm

Telephone

(650) 521-2279

Website

http://tessresearch.org/

Alerts

Be the first to know and let us send you an email when TESS Research Foundation for Slc13a5 Epilepsy posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.